Annual Meeting 2024 AACR Journals Concurrent Publications | American Association for Cancer Research

Annual Meeting 2024 AACR Journals Concurrent Publications | American Association for Cancer Research AACR Annual Meeting 2024: AACR Journals’ Concurrent Publications The AACR journal articles below published concurrently with presentations during the AACR Annual Meeting 2024. Saturday, April 6, 2024 Integration of Pan-Cancer Cell Line and Single-Cell Transcriptomic Profiles Enables Inference of Therapeutic Vulnerabilities in Heterogeneous Tumors R. Stephanie Huang, et al. Spatial…

Read the full article here

Source: aacrjournals.org

Categories: Oncologists1, General Medicine News

Tags: AACR24

Tweets with this article

Cancer Prevention Research

Check out the @AACR journal articles published concurrently with presentations during #AACR24. https://t.co/5eZlQiXFAo https://t.co/A7in91G69E

AACR IO

AACR IO: Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy

AACR November 18, 2024

First Clinical Trial of “Memory Like” Natural Killer Cells in Ovarian Cancer Opens at Dana-Farber

Investigators are opening a trial to evaluate a novel type of immune cellular therapy in patients with recurrent, platinum-resistant ovarian cancer.

OncLive.com November 18, 2024

Eric Topol (@erictopol.bsky.social)

A mechanism for why durable weight loss is so difficult: epigenetic memory of fat cells https://www.nature.com/articles/s41586-024-08165-7

Leonidas Platanias, MD November 18, 2024

Plenary Lecture to untangle drivers of racial disparities in breast cancer – SABCS Meeting News

Melissa Davis, PhD, will deliver a plenary lecture during the 2024 San Antonio Breast Cancer Symposium® about the social and biological drivers that underlie racial…

john doe 5 November 18, 2024

Events

Huntsman Cancer Institute at the University of Utah holds events for patients, families, caregivers, donors, and friends. We also sponsor conferences and seminars on topics…

Huntsman Cancer Inst November 18, 2024

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally…

Oncology Learning Network November 18, 2024

Related Articles